Bolden Therapeutics is developing first-in-class antisense oligonucleotides designed to promote neurogenesis as potential treatments for central nervous system illnesses including Alzheimer’s disease. The company has begun testing candidate antisense oligonucleotides in vivo and intends to advance preclinical development. It closed a $1.5M pre-seed convertible note financing to support those preclinical programs. The round was led by Resolute Venture Partners and included Slater Technology Fund, Lifespan Vision Ventures and multiple angel investors. Bolden’s foundational research originated from two Brown University research labs and the company received two ‘Golden Tickets’ from Biogen allowing residency at LabCentral and sponsored lab space. Its current research facility is located at the Tufts Launchpad | biolabs incubator. The company is led by Co-Founder and CEO Johnny Page alongside scientific co-founders Dr. Justin Fallon and Dr. Ashley Webb.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Jan 2024